private:acarix
|
735472
|
Dec 3rd, 2020 12:00AM
|
Acarix
|
673
|
14.00
|
Open
|
Medical Device
|
Dec 3rd, 2020 08:36AM
|
Dec 3rd, 2020 08:36AM
|
Acarix is a Swedish MedTech company founded in 2009, marketing the CADScor®System – the innovative, non-invasive and ultra-sensitive analytical device designed to support a safe, reliable and cost-effective rule-out of significant coronary artery disease (CAD) at the very first stage of the diagnostic pathway.
Recent studies have shown that as few as 6-10% of patients referred to non-invasive testing suffer from significant CAD, meaning that nine out of ten patients should be ruled-out from further investigations.1,2,3,4 With 97% confidence (negative predictive value), the CADScor®System can rule out up to 50% of the patients who experience symptoms such as chest pain, but who suffer from another illness than CAD. The diagnostic aid works as a support for decisions on how to continue the diagnostic pathway and reduce the number of referrals to costly investigations. The CADScor®System helps saving costs for the healthcare system, while also avoiding long waiting times and unnecessary stress for the patient.
Acarix was established in 2009 as a spin-off from Coloplast A/S, a research and development collaboration based on pioneering research from the Aalborg University in Denmark. Since 2010, the Danish investors SEED Capital and Sunstone Life Science Ventures has supported Acarix towards its market introduction. After receiving the CE-mark, Acarix was listed on Nasdaq First North Premier in 2016. The first market introduction took place in Germany in 2017. Today, the CADScor®System is also available in Scandinavia, UK, Austria and Schweiz. Our headquarters are in Malmö, Sweden, with a sales office outside of Copenhagen, Denmark.
|
Open
|
Acoustics, Heart murmurs, Diagnostic aid , Stable Chestpain, Coronary Artery Disease
|
Open
|
Jungmansgatan 12
|
Malmö
|
Skane County
|
SE
|
211 11
|
|
Acarix
|
Health Care
|
Pharmaceuticals & Biotechnology
|
private:acarix
|
735472
|
Dec 2nd, 2020 12:00AM
|
Acarix
|
672
|
14.00
|
Open
|
Medical Device
|
Dec 2nd, 2020 10:32AM
|
Dec 2nd, 2020 10:32AM
|
Acarix is a Swedish MedTech company founded in 2009, marketing the CADScor®System – the innovative, non-invasive and ultra-sensitive analytical device designed to support a safe, reliable and cost-effective rule-out of significant coronary artery disease (CAD) at the very first stage of the diagnostic pathway.
Recent studies have shown that as few as 6-10% of patients referred to non-invasive testing suffer from significant CAD, meaning that nine out of ten patients should be ruled-out from further investigations.1,2,3,4 With 97% confidence (negative predictive value), the CADScor®System can rule out up to 50% of the patients who experience symptoms such as chest pain, but who suffer from another illness than CAD. The diagnostic aid works as a support for decisions on how to continue the diagnostic pathway and reduce the number of referrals to costly investigations. The CADScor®System helps saving costs for the healthcare system, while also avoiding long waiting times and unnecessary stress for the patient.
Acarix was established in 2009 as a spin-off from Coloplast A/S, a research and development collaboration based on pioneering research from the Aalborg University in Denmark. Since 2010, the Danish investors SEED Capital and Sunstone Life Science Ventures has supported Acarix towards its market introduction. After receiving the CE-mark, Acarix was listed on Nasdaq First North Premier in 2016. The first market introduction took place in Germany in 2017. Today, the CADScor®System is also available in Scandinavia, UK, Austria and Schweiz. Our headquarters are in Malmö, Sweden, with a sales office outside of Copenhagen, Denmark.
|
Open
|
Acoustics, Heart murmurs, Diagnostic aid , Stable Chestpain, Coronary Artery Disease
|
Open
|
Jungmansgatan 12
|
Malmö
|
Skane County
|
SE
|
211 11
|
|
Acarix
|
Health Care
|
Pharmaceuticals & Biotechnology
|
private:acarix
|
735472
|
Dec 1st, 2020 12:00AM
|
Acarix
|
671
|
14.00
|
Open
|
Medical Device
|
Dec 1st, 2020 09:36AM
|
Dec 1st, 2020 09:36AM
|
Acarix is a Swedish MedTech company founded in 2009, marketing the CADScor®System – the innovative, non-invasive and ultra-sensitive analytical device designed to support a safe, reliable and cost-effective rule-out of significant coronary artery disease (CAD) at the very first stage of the diagnostic pathway.
Recent studies have shown that as few as 6-10% of patients referred to non-invasive testing suffer from significant CAD, meaning that nine out of ten patients should be ruled-out from further investigations.1,2,3,4 With 97% confidence (negative predictive value), the CADScor®System can rule out up to 50% of the patients who experience symptoms such as chest pain, but who suffer from another illness than CAD. The diagnostic aid works as a support for decisions on how to continue the diagnostic pathway and reduce the number of referrals to costly investigations. The CADScor®System helps saving costs for the healthcare system, while also avoiding long waiting times and unnecessary stress for the patient.
Acarix was established in 2009 as a spin-off from Coloplast A/S, a research and development collaboration based on pioneering research from the Aalborg University in Denmark. Since 2010, the Danish investors SEED Capital and Sunstone Life Science Ventures has supported Acarix towards its market introduction. After receiving the CE-mark, Acarix was listed on Nasdaq First North Premier in 2016. The first market introduction took place in Germany in 2017. Today, the CADScor®System is also available in Scandinavia, UK, Austria and Schweiz. Our headquarters are in Malmö, Sweden, with a sales office outside of Copenhagen, Denmark.
|
Open
|
Acoustics, Heart murmurs, Diagnostic aid , Stable Chestpain, Coronary Artery Disease
|
Open
|
Jungmansgatan 12
|
Malmö
|
Skane County
|
SE
|
211 11
|
|
Acarix
|
Health Care
|
Pharmaceuticals & Biotechnology
|
private:acarix
|
735472
|
Nov 30th, 2020 12:00AM
|
Acarix
|
670
|
14.00
|
Open
|
Medical Device
|
Nov 30th, 2020 09:55AM
|
Nov 30th, 2020 09:55AM
|
Acarix is a Swedish MedTech company founded in 2009, marketing the CADScor®System – the innovative, non-invasive and ultra-sensitive analytical device designed to support a safe, reliable and cost-effective rule-out of significant coronary artery disease (CAD) at the very first stage of the diagnostic pathway.
Recent studies have shown that as few as 6-10% of patients referred to non-invasive testing suffer from significant CAD, meaning that nine out of ten patients should be ruled-out from further investigations.1,2,3,4 With 97% confidence (negative predictive value), the CADScor®System can rule out up to 50% of the patients who experience symptoms such as chest pain, but who suffer from another illness than CAD. The diagnostic aid works as a support for decisions on how to continue the diagnostic pathway and reduce the number of referrals to costly investigations. The CADScor®System helps saving costs for the healthcare system, while also avoiding long waiting times and unnecessary stress for the patient.
Acarix was established in 2009 as a spin-off from Coloplast A/S, a research and development collaboration based on pioneering research from the Aalborg University in Denmark. Since 2010, the Danish investors SEED Capital and Sunstone Life Science Ventures has supported Acarix towards its market introduction. After receiving the CE-mark, Acarix was listed on Nasdaq First North Premier in 2016. The first market introduction took place in Germany in 2017. Today, the CADScor®System is also available in Scandinavia, UK, Austria and Schweiz. Our headquarters are in Malmö, Sweden, with a sales office outside of Copenhagen, Denmark.
|
Open
|
Acoustics, Heart murmurs, Diagnostic aid , Stable Chestpain, Coronary Artery Disease
|
Open
|
Jungmansgatan 12
|
Malmö
|
Skane County
|
SE
|
211 11
|
|
Acarix
|
Health Care
|
Pharmaceuticals & Biotechnology
|
private:acarix
|
735472
|
Nov 29th, 2020 12:00AM
|
Acarix
|
668
|
14.00
|
Open
|
Medical Device
|
Nov 29th, 2020 04:41PM
|
Nov 29th, 2020 04:41PM
|
Acarix is a Swedish MedTech company founded in 2009, marketing the CADScor®System – the innovative, non-invasive and ultra-sensitive analytical device designed to support a safe, reliable and cost-effective rule-out of significant coronary artery disease (CAD) at the very first stage of the diagnostic pathway.
Recent studies have shown that as few as 6-10% of patients referred to non-invasive testing suffer from significant CAD, meaning that nine out of ten patients should be ruled-out from further investigations.1,2,3,4 With 97% confidence (negative predictive value), the CADScor®System can rule out up to 50% of the patients who experience symptoms such as chest pain, but who suffer from another illness than CAD. The diagnostic aid works as a support for decisions on how to continue the diagnostic pathway and reduce the number of referrals to costly investigations. The CADScor®System helps saving costs for the healthcare system, while also avoiding long waiting times and unnecessary stress for the patient.
Acarix was established in 2009 as a spin-off from Coloplast A/S, a research and development collaboration based on pioneering research from the Aalborg University in Denmark. Since 2010, the Danish investors SEED Capital and Sunstone Life Science Ventures has supported Acarix towards its market introduction. After receiving the CE-mark, Acarix was listed on Nasdaq First North Premier in 2016. The first market introduction took place in Germany in 2017. Today, the CADScor®System is also available in Scandinavia, UK, Austria and Schweiz. Our headquarters are in Malmö, Sweden, with a sales office outside of Copenhagen, Denmark.
|
Open
|
Acoustics, Heart murmurs, Diagnostic aid , Stable Chestpain, Coronary Artery Disease
|
Open
|
Jungmansgatan 12
|
Malmö
|
Skane County
|
SE
|
211 11
|
|
Acarix
|
Health Care
|
Pharmaceuticals & Biotechnology
|
private:acarix
|
735472
|
Nov 28th, 2020 12:00AM
|
Acarix
|
668
|
14.00
|
Open
|
Medical Device
|
Nov 28th, 2020 12:33PM
|
Nov 28th, 2020 12:33PM
|
Acarix is a Swedish MedTech company founded in 2009, marketing the CADScor®System – the innovative, non-invasive and ultra-sensitive analytical device designed to support a safe, reliable and cost-effective rule-out of significant coronary artery disease (CAD) at the very first stage of the diagnostic pathway.
Recent studies have shown that as few as 6-10% of patients referred to non-invasive testing suffer from significant CAD, meaning that nine out of ten patients should be ruled-out from further investigations.1,2,3,4 With 97% confidence (negative predictive value), the CADScor®System can rule out up to 50% of the patients who experience symptoms such as chest pain, but who suffer from another illness than CAD. The diagnostic aid works as a support for decisions on how to continue the diagnostic pathway and reduce the number of referrals to costly investigations. The CADScor®System helps saving costs for the healthcare system, while also avoiding long waiting times and unnecessary stress for the patient.
Acarix was established in 2009 as a spin-off from Coloplast A/S, a research and development collaboration based on pioneering research from the Aalborg University in Denmark. Since 2010, the Danish investors SEED Capital and Sunstone Life Science Ventures has supported Acarix towards its market introduction. After receiving the CE-mark, Acarix was listed on Nasdaq First North Premier in 2016. The first market introduction took place in Germany in 2017. Today, the CADScor®System is also available in Scandinavia, UK, Austria and Schweiz. Our headquarters are in Malmö, Sweden, with a sales office outside of Copenhagen, Denmark.
|
Open
|
Acoustics, Heart murmurs, Diagnostic aid , Stable Chestpain, Coronary Artery Disease
|
Open
|
Jungmansgatan 12
|
Malmö
|
Skane County
|
SE
|
211 11
|
|
Acarix
|
Health Care
|
Pharmaceuticals & Biotechnology
|
private:acarix
|
735472
|
Nov 27th, 2020 12:00AM
|
Acarix
|
664
|
14.00
|
Open
|
Medical Device
|
Nov 27th, 2020 08:53AM
|
Nov 27th, 2020 08:53AM
|
Acarix is a Swedish MedTech company founded in 2009, marketing the CADScor®System – the innovative, non-invasive and ultra-sensitive analytical device designed to support a safe, reliable and cost-effective rule-out of significant coronary artery disease (CAD) at the very first stage of the diagnostic pathway.
Recent studies have shown that as few as 6-10% of patients referred to non-invasive testing suffer from significant CAD, meaning that nine out of ten patients should be ruled-out from further investigations.1,2,3,4 With 97% confidence (negative predictive value), the CADScor®System can rule out up to 50% of the patients who experience symptoms such as chest pain, but who suffer from another illness than CAD. The diagnostic aid works as a support for decisions on how to continue the diagnostic pathway and reduce the number of referrals to costly investigations. The CADScor®System helps saving costs for the healthcare system, while also avoiding long waiting times and unnecessary stress for the patient.
Acarix was established in 2009 as a spin-off from Coloplast A/S, a research and development collaboration based on pioneering research from the Aalborg University in Denmark. Since 2010, the Danish investors SEED Capital and Sunstone Life Science Ventures has supported Acarix towards its market introduction. After receiving the CE-mark, Acarix was listed on Nasdaq First North Premier in 2016. The first market introduction took place in Germany in 2017. Today, the CADScor®System is also available in Scandinavia, UK, Austria and Schweiz. Our headquarters are in Malmö, Sweden, with a sales office outside of Copenhagen, Denmark.
|
Open
|
Acoustics, Heart murmurs, Diagnostic aid , Stable Chestpain, Coronary Artery Disease
|
Open
|
Jungmansgatan 12
|
Malmö
|
Skane County
|
SE
|
211 11
|
|
Acarix
|
Health Care
|
Pharmaceuticals & Biotechnology
|
private:acarix
|
735472
|
Nov 26th, 2020 12:00AM
|
Acarix
|
660
|
14.00
|
Open
|
Medical Device
|
Nov 26th, 2020 09:54AM
|
Nov 26th, 2020 09:54AM
|
Acarix is a Swedish MedTech company founded in 2009, marketing the CADScor®System – the innovative, non-invasive and ultra-sensitive analytical device designed to support a safe, reliable and cost-effective rule-out of significant coronary artery disease (CAD) at the very first stage of the diagnostic pathway.
Recent studies have shown that as few as 6-10% of patients referred to non-invasive testing suffer from significant CAD, meaning that nine out of ten patients should be ruled-out from further investigations.1,2,3,4 With 97% confidence (negative predictive value), the CADScor®System can rule out up to 50% of the patients who experience symptoms such as chest pain, but who suffer from another illness than CAD. The diagnostic aid works as a support for decisions on how to continue the diagnostic pathway and reduce the number of referrals to costly investigations. The CADScor®System helps saving costs for the healthcare system, while also avoiding long waiting times and unnecessary stress for the patient.
Acarix was established in 2009 as a spin-off from Coloplast A/S, a research and development collaboration based on pioneering research from the Aalborg University in Denmark. Since 2010, the Danish investors SEED Capital and Sunstone Life Science Ventures has supported Acarix towards its market introduction. After receiving the CE-mark, Acarix was listed on Nasdaq First North Premier in 2016. The first market introduction took place in Germany in 2017. Today, the CADScor®System is also available in Scandinavia, UK, Austria and Schweiz. Our headquarters are in Malmö, Sweden, with a sales office outside of Copenhagen, Denmark.
|
Open
|
Acoustics, Heart murmurs, Diagnostic aid , Stable Chestpain, Coronary Artery Disease
|
Open
|
Jungmansgatan 12
|
Malmö
|
Skane County
|
SE
|
211 11
|
|
Acarix
|
Health Care
|
Pharmaceuticals & Biotechnology
|
private:acarix
|
735472
|
Nov 25th, 2020 12:00AM
|
Acarix
|
656
|
14.00
|
Open
|
Medical Device
|
Nov 25th, 2020 11:52AM
|
Nov 25th, 2020 11:52AM
|
Acarix is a Swedish MedTech company founded in 2009, marketing the CADScor®System – the innovative, non-invasive and ultra-sensitive analytical device designed to support a safe, reliable and cost-effective rule-out of significant coronary artery disease (CAD) at the very first stage of the diagnostic pathway.
Recent studies have shown that as few as 6-10% of patients referred to non-invasive testing suffer from significant CAD, meaning that nine out of ten patients should be ruled-out from further investigations.1,2,3,4 With 97% confidence (negative predictive value), the CADScor®System can rule out up to 50% of the patients who experience symptoms such as chest pain, but who suffer from another illness than CAD. The diagnostic aid works as a support for decisions on how to continue the diagnostic pathway and reduce the number of referrals to costly investigations. The CADScor®System helps saving costs for the healthcare system, while also avoiding long waiting times and unnecessary stress for the patient.
Acarix was established in 2009 as a spin-off from Coloplast A/S, a research and development collaboration based on pioneering research from the Aalborg University in Denmark. Since 2010, the Danish investors SEED Capital and Sunstone Life Science Ventures has supported Acarix towards its market introduction. After receiving the CE-mark, Acarix was listed on Nasdaq First North Premier in 2016. The first market introduction took place in Germany in 2017. Today, the CADScor®System is also available in Scandinavia, UK, Austria and Schweiz. Our headquarters are in Malmö, Sweden, with a sales office outside of Copenhagen, Denmark.
|
Open
|
Acoustics, Heart murmurs, Diagnostic aid , Stable Chestpain, Coronary Artery Disease
|
Open
|
Jungmansgatan 12
|
Malmö
|
Skane County
|
SE
|
211 11
|
|
Acarix
|
Health Care
|
Pharmaceuticals & Biotechnology
|
private:acarix
|
735472
|
Nov 24th, 2020 12:00AM
|
Acarix
|
655
|
14.00
|
Open
|
Medical Device
|
Nov 24th, 2020 08:41AM
|
Nov 24th, 2020 08:41AM
|
Acarix is a Swedish MedTech company founded in 2009, marketing the CADScor®System – the innovative, non-invasive and ultra-sensitive analytical device designed to support a safe, reliable and cost-effective rule-out of significant coronary artery disease (CAD) at the very first stage of the diagnostic pathway.
Recent studies have shown that as few as 6-10% of patients referred to non-invasive testing suffer from significant CAD, meaning that nine out of ten patients should be ruled-out from further investigations.1,2,3,4 With 97% confidence (negative predictive value), the CADScor®System can rule out up to 50% of the patients who experience symptoms such as chest pain, but who suffer from another illness than CAD. The diagnostic aid works as a support for decisions on how to continue the diagnostic pathway and reduce the number of referrals to costly investigations. The CADScor®System helps saving costs for the healthcare system, while also avoiding long waiting times and unnecessary stress for the patient.
Acarix was established in 2009 as a spin-off from Coloplast A/S, a research and development collaboration based on pioneering research from the Aalborg University in Denmark. Since 2010, the Danish investors SEED Capital and Sunstone Life Science Ventures has supported Acarix towards its market introduction. After receiving the CE-mark, Acarix was listed on Nasdaq First North Premier in 2016. The first market introduction took place in Germany in 2017. Today, the CADScor®System is also available in Scandinavia, UK, Austria and Schweiz. Our headquarters are in Malmö, Sweden, with a sales office outside of Copenhagen, Denmark.
|
Open
|
Acoustics, Heart murmurs, Diagnostic aid , Stable Chestpain, Coronary Artery Disease
|
Open
|
Jungmansgatan 12
|
Malmö
|
Skane County
|
SE
|
211 11
|
|
Acarix
|
Health Care
|
Pharmaceuticals & Biotechnology
|